Where Will Exelixis Be in 5 Years? 1 Experimental Drug Could Change Everything
Exelixis faces a patent cliff for its blockbuster drug Cabometyx by 2030, but the company's future hinges on zanzalintinib, an experimental cancer drug expected to receive FDA approval by March 2027. The drug showed modest survival benefits in metastatic colorectal cancer trials and could generate $5 billion in sales by 2033 if approved across multiple indications. Despite regulatory delays and competitive pressures, Exelixis' shares appear reasonably valued at 16.3x forward earnings.